VEGFA and osteosarcoma: Notably, the benefit of anti-VEGF agents in osteosarcoma appears to be modest and transient, suggesting a role for earlier introduction (as maintenance therapy after a first line of treatment for instance), or combination with other drug classes (when allowed by the toxicity profile of each drug).